Stock Ratings / Health Care / BMY / insiders

VRTX (80) SNY (59) GSK (57) PFE (73) ⌘ Pro Terminal →

Bristol-Myers Squibb Company (BMY) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$62.48 +1.78% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $62.56

Bristol-Myers Squibb Company (BMY) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 63/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.9% avg 90D alpha vs SPY) →

ROARABLE C • HOLD / WATCH Cap $125.40B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BMY Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BMY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Bristol-Myers Squibb Company (NYSE: BMY) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $62.48 (+1.78% 1D, market cap $125.40B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, BMY ranks #141 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BMY compare to VRTX and SNY in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BMY carries a Roarable C (63/100 RQD), trailing P/E of 17.8x, gross margin of 71.1%, and ROIC of 13.3%. By comparison, VRTX (Vertex Pharmaceuticals Incorporated) holds a B+ grade (80/100 RQD, P/E 34.6x, ROIC 20.0%, cap $136.87B) and SNY (Sanofi ADS) posts a C- grade (59/100 RQD, P/E 32.8x, ROIC 9.9%, cap $105.19B). Among the 5-stock peer group, BMY leads on earnings multiple (17.8x) while VRTX leads on capital efficiency (20.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BMY?

▼

Per BMY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000014272), Bristol-Myers Squibb Company generated $48.19B in revenue (-0.2% YoY), $7.05B in net income, and $12.85B in free cash flow against $90.04B in total assets and $42.85B in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $62.56 (+0.13%)🧬 Cannibal Buyback (-2.64% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 26.7% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 63/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.9% avg 90D alpha vs SPY • 54.8% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE+2.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BMY)Realized 20D OHLCV Swing Band: ±5.9%

Deterministic 5-Pillar Attribution (63/100 Composite)

🔍 WHY BMY SCORES 63/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Insider Conviction & Share Dilution+17/20 pts (27% of score)

SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)

▲ #2 Bullish Driver: Whale & Options Positioning+12/20 pts (19% of score)

20D Institutional Volume Accumulation (±5.9% realized swing band)

▼ #1 Drag / Risk Factor: Macro Regime Fit11/20 pts (-9 pt drag)

Macro rate sensitivity & RSI-14 (50.4) create a -9 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$56.67+8.8% Next Q

Q2 (-2Q)

Grade C$61.68-0.2% Next Q

Q3 (-1Q)

Grade C$61.55+1.5% Next Q

Current

Grade C$62.48+0.9% Hist 90D α

Trajectory: C (55) → C (63)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the BMY Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 63/100 (C) score, BMY faces multiple-compression risk if 17.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 68.6% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($62.57) or 200D SMA ($60.00) invalidates the momentum regime and cuts Target Base ($63.89) toward Bear Floor ($49.83).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BMY• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BMY Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 63%NO 37%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

BMY Smart-Money Thermometer: HEAVY INSIDER & 13F ACCUMULATION

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (BMY)

No recent open-market Form 4 cluster sales or emergency dumps flagged on BMY. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (BMY Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BMY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +8.89%📐 WEDGE COMPRESSION COIL

2026-11-02O $60.57H $62.48L $60.57C $62.48VOL 14.77M

RES: $63.87SUP: $56.66SMA50: $62.57SMA200: $60.00

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BMY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BMY Butterfly Map → + Track BMY →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

10.9%/yr Implied 5Y Growth

vs. -0.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BMY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BMY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BMY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BMY)

Health Care Rank #141 of 1016 ⚔️ VRTX vs BMY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BMY vs. VRTX, SNY, GSK, PFE)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Bristol-Myers Squibb Company (BMY) ranks #141 by composite RQD confidence (63/100, grade C) and #18 by equity capitalization ($125.40B). Within this direct 5-issuer industry benchmark cohort, BMY leads on earnings valuation at 17.8x trailing P/E, while VRTX leads on capital efficiency and profitability with 20.0% ROIC and 86.2% gross margin. VRTX currently holds the highest overall quantitative score in the immediate peer group at 80/100 (B+) compared with BMY at 63/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BMY ACTIVE Bristol-Myers Squibb Company	C	63/100	17.8x	71.1%	13.3%	+1.78%	$125.40B	Benchmark Subject
VRTX Vertex Pharmaceuticals Incorporated	B+	80/100	34.6x	86.2%	20.0%	+3.50%	$136.87B	/vrtx-vs-bmy →
SNY Sanofi ADS	C-	59/100	32.8x	—	9.9%	+2.81%	$105.19B	/sny-vs-bmy →
GSK GSK plc American	D+	57/100	32.8x	—	9.9%	+1.71%	$98.47B	/gsk-vs-bmy →
PFE Pfizer Inc.	B	73/100	22.0x	74.3%	5.1%	+1.90%	$170.71B	/pfe-vs-bmy →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000014272

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Bristol-Myers Squibb Company (BMY) reported GAAP revenue of $48.19B (-0.2% vs. FY2024 revenue of $48.30B , and +7.1% cumulative change since FY2023) , GAAP net income of $7.05B, operating cash flow of $14.16B, and free cash flow of $12.85B (-7.9% YoY). On the balance sheet, BMY closed FY2025 with $90.04B in total assets against $42.85B in total debt (Altman Z-Score: 2.24, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$48.19B	$7.05B	$14.16B	$12.85B	$90.04B	$42.85B
FY2024 (FY)	2024-12-31	$48.30B	-$8.95B	$15.19B	$13.94B	$92.60B	$47.60B
FY2023 (FY)	2023-12-31	$45.01B	$8.03B	$13.86B	$11.83B	$68.97B	$16.14B

3. BMY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BMY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does BMY compare to VRTX and SNY in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for BMY?

Where is BMY trading relative to its 50-day, 200-day, and 52-week technical levels?

BMY last traded at $62.48 (+1.78% on volume of 12,668,096 shares), positioning the stock -0.14% below its 50-day simple moving average ($62.57) and +4.13% above its 200-day simple moving average ($60.00). Across its 52-week range of $45.27 to $68.64, BMY sits at the 73.6% percentile with a 14-day RSI of 50.4 (NEUTRAL RANGE) and an implied next-earnings move of ±5.9% ($58.79 to $66.17).

BMY Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are BMY insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies BMY leadership and institutional positioning as: HEAVY INSIDER & 13F ACCUMULATION.

Direct Sub-Reports: BMY RQD Cockpit BMY 12M Forecast BMY Earnings & Move BMY Dividends & DRIP BMY Insiders & 13F BMY Whale Options BMY Profit Sankey BMY News & Why

ROARABLE RATING BRIEF • RQD 63/100 (C) ✓ STAGE-C NUMBER FIREWALL VERIFIED

BMY — Bristol-Myers Squibb Company: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:09:29Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, BMY scores 63 out of 100, a letter grade of C, with the verdict label "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars are:

Fundamental Cash Engine: 11 / 20. Per the RQD rating, this pillar reflects ROIC of 13.3% and an FCF yield of 10.24%. Cash generation is a clear strength, but the pillar score sits below mid-range, which suggests the market is not fully crediting that cash flow in the current framework.
Whale 13F Flow: 12 / 20. Per the RQD rating, this pillar captures institutional accumulation and options positioning. The score is modestly below half, indicating no strong, unambiguous institutional conviction signal in the source data.
Insider Conviction: 17 / 20. Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. It is the highest-scoring pillar, pointing to comparatively constructive insider and congressional activity, though the underlying trade-level detail is not provided in the source data.
Macro Regime Fit: 11 / 20. Per the RQD rating, this pillar reflects a beta of 0.98 and sector sensitivity. A beta near 1.0 means the stock has tracked broad market moves roughly one-for-one, offering neither a defensive cushion nor elevated leverage to the market.
Forensic Balance Sheet: 12 / 20. Per the RQD rating, this pillar reflects an Altman Z-Score of 2.24, a Piotroski F-Score of 7/9, and a Debt/Equity ratio of 2.32. The Piotroski score is strong, while leverage and the Altman reading suggest a balance sheet that is sound on operating quality but carries meaningful debt.

Investor implications. The upside drivers in the data are the high cash yield, the constructive insider pillar, and a forward P/E of 16.6 that sits below the trailing 17.8. The valuation tradeoff is that EV/EBITDA of 16.3 and Debt/Equity of 2.32 show the enterprise is not cheap on a capital-structure-adjusted basis. The composite score of 63 signals a balanced setup rather than a clear accumulation or avoidance case, so a prospective investor would need to weigh the cash-generation strength against leverage and the lack of strong institutional conviction. This is an educational reading of the factors, not personalized advice.

Snapshot

Price	Market Cap	P/E (TTM)	Forward P/E	EV/EBITDA	EPS (TTM)	Dividend Yield	Beta	52-Wk Range	ROIC %
61.39	$125.4B	17.8	16.6	16.3	3.45	4.02%	0.98	$45.27 - $68.64	13.3%

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$48194.0M	$8323.7M	$7054.0M	N/A	$12845.0M	$10209.0M	$42850.0M
FY 2024	$48300.0M	$-10558.6M	$-8948.0M	N/A	$13942.0M	$10346.0M	$47603.0M
FY 2023	$45006.0M	$9469.5M	$8025.0M	N/A	$11834.7M	N/A	$16139.3M

Per the SEC financials, FY 2025 shows a return to positive operating and net income following a FY 2024 loss, with free cash flow reported at $12845.0M. Per the market data, gross margin is 71.1%, operating margin 17.9%, and net margin 14.6%, with ROIC of 13.3%. Per the RQD forensic pillar, the Altman Z-Score is 2.24 and the Piotroski F-Score is 7/9, while Debt/Equity is 2.32. Debt in the SEC financials declined from $47603.0M in FY 2024 to $42850.0M in FY 2025, while the source data shows no balance-sheet period-end cash for FY 2023.

Recent Catalysts & News Wire Analysis

The news wire contains six items, all tagged to BMY and of the same general kind: market-trend and commentary pieces rather than discrete corporate events. Headlines reference a "pullback" as an opportunity, an institutional-positioning angle, a forward-earnings valuation argument, and an upcoming Q3 earnings event. Items are marked with impact labels of "MARKET WIRE" or "CATALYST" and light indicators of GREEN or YELLOW. Specific risk-watch items are Not available in source data beyond the commentary framing. The Butterfly Supply-Chain Graph reports no proprietary signals; see the next section.

Open Questions

What specific product and revenue drivers account for the FY 2025 operating turnaround after the FY 2024 loss?
What were the drivers of the FY 2024 operating loss, and were they one-time or recurring?
What is the composition of the Congressional and Form 4 insider flow behind the 17/20 insider pillar score?
What is the balance-sheet period-end cash for FY 2023, and how does the $42850.0M debt load compare with maturity schedules?
What institutional 13F positioning and options data underlie the 12/20 whale pillar?

BMY Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Bristol-Myers Squibb Company (BMY) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BMY Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 8h ago

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

Yahoo Finance report covering Bristol-Myers Squibb Company (BMY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Seeking Alpha • 11h ago

Bristol-Myers Squibb: Balanced Segment Growth, The Pullback Is An Opportunity

Seeking Alpha report covering Bristol-Myers Squibb Company (BMY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 14h ago

Bristol Myers (BMY) Stock is Trading Below 10 Times Forward Earnings. Here’s Why it Matters

Yahoo Finance report covering Bristol-Myers Squibb Company (BMY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Seeking Alpha • 17h ago

Bristol-Myers Squibb: Why I'm Bullish Ahead Of Q3 Earnings (NYSE:BMY)

Seeking Alpha report covering Bristol-Myers Squibb Company (BMY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 20h ago

Bristol-Myers Squibb Company (BMY) stock price, news, quote and history

Yahoo Finance UK report covering Bristol-Myers Squibb Company (BMY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 23h ago

Bristol Myers Squibb: The New Portfolio Is Starting To Carry More Of The Business

Seeking Alpha report covering Bristol-Myers Squibb Company (BMY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today

Yahoo Finance report covering Bristol-Myers Squibb Company (BMY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

Bristol-Myers Squibb: Patent Cliff Is Still A Problem (NYSE:BMY)

Seeking Alpha report covering Bristol-Myers Squibb Company (BMY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BMY Bull vs. Bear Conversation Board — What's Your Call at $62.48?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BMY 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $66.30 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is BMY (C • RQD 63/100) a Buy at $61.39?

Welcome to the BMY (Bristol-Myers Squibb Company) Roar Pit. Current RQD Composite is 63/100 (Roarable Hold — Fair / Balanced Risk-Reward) in Biotechnology: Pharmaceutical Preparations. Bulls point to capital efficiency (13.3% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $46.66 (-24.0%)

Spot @ $61.39

Pump the brakes on BMY — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on BMY, but look at what you are paying: 17.8x trailing P/E with 71.1% gross margins. Unless Bristol-Myers Squibb Company expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $71.83 (+17.0%)

Spot @ $61.39

BMY cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on BMY, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $61.39 (52-wk range $45.27 - $68.64), any beat on forward guidance forces shorts and underweight funds to chase.